Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

Key Points

• Psilocybin-assisted therapy significantly reduces relapse rates in alcohol use disorder patients, potentially aiding recovery.
• Patients receiving psilocybin therapy showed a 50% reduction in relapse within 6 months compared to the control group.
• Conducted as a phase 2 randomized clinical trial, this research supports the therapeutic use of psilocybin for addiction treatment.
• Findings may enable broader applications of psilocybin in interventions for various substance use disorders.